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Abstract: Due to their small particle size and large and modifiable surface, nanoparticles 
have unique advantages compared with other drug carriers. As a research focus in recent years, 
polyethylene glycol–polylactic acid (PEG–PLA) block copolymer and its end-group derivative 
nanoparticles can enhance the drug loading of hydrophobic drugs, reduce the burst effect, avoid 
being engulfed by phagocytes, increase the circulation time of drugs in blood, and improve 
bioavailability. Additionally, due to their smaller particle size and modified surface, these 
nanoparticles can accumulate in inflammation or target locations to enhance drug efficacy and 
reduce toxicity. Recent advances in PEG–PLA block copolymer nanoparticles, including the 
synthesis of PEG–PLA and the preparation of PEG–PLA nanoparticles, were introduced in this 
study, in particular the drug release and modifiable characteristics of PEG–PLA nanoparticles 
and their application in pharmaceutical preparations.
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Introduction
Polylactic acid (PLA) is a synthetic biodegradable polymer. In the aquatic environment, 
it hydrolyzes into nontoxic hydroxyl-carboxylic acid through ester bond cleavage and 
then is metabolized into water and carbon dioxide through a citric acid cycle. Due to its 
suitable biodegradability, good security, low immunity, and good mechanical strength, 
PLA has been approved by the US Food and Drug Administration for application in 
tissue engineering, medical materials, drug carriers, for example,1 and it has good 
prospects for peptides, proteins, vaccines, anticancer drugs, and other drug carriers. 
However, PLA applications are limited due to its weak hydrophilicity, excessively 
long degradation time, and low drug loading of polar drugs.2 On the other hand, poly-
ethylene glycol (PEG) has many advantages, such as good hydrophilicity, flexibility, 
antiphagocytosis against macrophages, resistance to immunological recognition, non-
combination with proteins, and biocompatibility.3–6 Through copolymerization with 
PEG, PLA can be improved in hydrophilicity, degradation rate,7 and crystallization,8 
showing great potential for development in drug delivery. The degradation products of 
PEG–PLA block copolymer can enter the tricarboxylic acid cycle or be eliminated by 
the kidney. Thus, in low concentration the copolymer is nontoxic and not accumulative 
in vivo.9 The copolymerization of PLA and PEG can increase the drug loading, reduce 
the burst effect, and prolong the in vivo residence time of drugs and avoid them being 
engulfed by macrophages. The synthesis of PEG–PLA block copolymer and its end-
group derivatives and the preparation of PEG–PLA nanoparticles will be discussed International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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in this paper, in particular their drug release and   modifiable 
characteristics and their application in pharmaceutical 
preparations.
Synthesis of PEG–PLA block 
copolymer and its end-group 
derivatives
Ring-opening polymerization  
of PeG and lactide
These polymers may be synthesized by ring-opening 
polymerization between PEG or its end-group derivatives 
(such as methoxy polyethylene glycol [mPEG]) and lactide 
(Figure 1).10 Tin salts are the commonly used catalysts, 
especially stannous compounds with a higher catalytic effi-
ciency. However, due to the toxicity of these heavy metal 
compounds, acetic acid bismuth was used as an initiator by 
Kricheldorf et al.11 It was found that in the copolymerization 
system of l-lactide and PEG tetramer, the length of poly-
mer chain could be controlled by changing the proportion 
of monomer and initiator, and copolymers with different 
molecular structures could be synthesized, such as A-B 
stellate copolymer, A-B-A triblock copolymer, multiblock 
copolymer, and reticular copolymer.
Anionic ring-opening polymerization
In anionic ring-opening polymerization, common catalysts 
include potassium alkoxide,12 sodium alkoxide,13 and butyl 
lithium. Otsuka et al13 synthesized 3,3-diethoxy-potassium 
propanol ([C2H5O]2CHCH2OK) with the initial reactants 
3,3-diethoxy-propanol ([C2H5O]2CHCH2OH) and potas-
sium naphthalene (K-Naph) and the solvent tetrahydrofuran 
(THF), and then synthesized α-acetal-PEG–PLA block 
copolymer through anionic ring-opening polymerization 
with ethylene oxide and lactic acid (LA) as reactants 
and   3,3-diethoxy-potassium propanol as an initiator 
(Figure 2).
Synthesis of PeG–PLA end-group 
derivatives
The physical and chemical properties of PEG–PLA copoly-
mers can be improved by modifying the hydroxyl of the PEG 
end-group for better-loading hydrophobic, gene, and protein 
drugs.14,15 The common end-group forms of PEG–PLA 
derivatives include hydroformylation, propylene acylation, 
and amination.16 For example, Salem et al17 first linked biotin 
with PEG to synthesize biotin–PEG and then linked PLA 
with biotin–PEG to synthesize biotin–PEG–PLA polymer 
through ring-opening polymerization.
Preparation of PEG–PLA block 
copolymer nanoparticles
Using different compositions and preparation methods, 
amphiphilic block copolymers such as PEG–PLA block 
copolymer can be prepared into various forms of nanopar-
ticles, including nanomicelles, polymersomes, nanospheres, 
and nanocapsules (Figure 3).18
Preparation of PeG–PLA block 
copolymer nanomicelles
The method of preparation of PEG–PLA block copolymer 
nanomicelles mainly depends on the hydrophilicity of 
copolymers. The hydrophilic copolymer can form micelles 
by self-assembly in water. The direct dissolution method is 
most commonly used, ie, after being dissolved directly in 
water (they are able to be heated), the copolymers may form 
the transparent micellar solution immediately above its criti-
cal micelle concentration.19 Another is the film rehydration 
method, ie, copolymers and drugs are dissolved in volatile 
solvent to form a membrane after vaporizing solvent, and then 
the micelles can be formed by adding buffer solution or water 
as well as stirring and dissolving copolymer membranes.20 If 
the copolymer is insoluble in water, organic solvents may be 
used. The copolymer is first dissolved in the organic solvent 
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Figure 1 Synthesis scheme of mPeG–PLA.10
Copyright © 2010, elsevier Limited. Reproduced with permission from Zhang X, Li Y, Chen X, et al. Synthesis and characterization of the paclitaxel/MPeG-PLA block 
copolymer conjugate. Biomaterials. 2005;26(14):2121–2128. 
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(or water-mixed solvent), and then the organic solvent is 
removed by dialysis or evaporation.21
Preparation of PeG–PLA block 
copolymer polymersomes
Some preparation methods of liposomes, such as the 
injection method, film rehydration method, and ultrasonic 
dispersion method, can also be used to prepare copolymer 
polymersomes. The solvent injection method was adopted 
by Jain and Kumar22 to prepare amphotericin B-loaded 
polymersomes. In the film   rehydration method, copolymers 
are dissolved in volatile organic solvents, the membranes 
form after the rotary evaporation of organic solvents, and then 
the copolymer polymersomes form after adding buffer solu-
tion and stirring constantly with sonication and extrusion.23
Preparation of PeG–PLA block 
copolymer nanospheres
The preparation methods of copolymer nanospheres 
include the emulsification solvent evaporation method and 
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Figure 2 Synthesis scheme of acetal-ended poly(ethylene glycol)–poly(lactic acid) copolymers.13 
Copyright © 2010, American Chemical Society. Reproduced with permission from Otsuka H, Nagasaki Y, Kataoka K. Surface characterization of functionalized polylactide 
through the coating with heterobifunctional poly(ethylene glycol)/polylactide block copolymers. Biomacromolecules. 2000;1(1):39–48.
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Figure 3 Classification of nanoparticle drug delivery systems and their general characteristics.18
Copyright © 2010, Elsevier Limited. Reproduced with permission from Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer 
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  emulsification solvent diffusion method. The process is 
generally divided into two steps. The first step is emulsifica-
tion, ie, the copolymer and drugs are dissolved in organic 
solvent and then the emulsion is formed by adding into the 
water phase and stirring. The second step is to remove the 
organic solvent in the emulsion by evaporation or dialysis.24 
  Venkatraman et al25 used the emulsification solvent evapo-
ration method to prepare the PLA–PEG–PLA nanospheres. 
First, the copolymer was dissolved in organic solvent 
(acetone, THF, dimethylformamide, or dimethylacetamide) 
and mixed with deionized water by stirring. Then, acetone 
or THF was removed by evaporation, dimethylformamide or 
dimethylacetamide was removed by dialysis, and finally the 
nanospheres were obtained after freeze dehydration.
Preparation of PeG–PLA block 
copolymer nanocapsules
The interfacial polymerization method is commonly used 
to prepare PEG–PLA nanocapsules, ie, drugs and block 
copolymers are dissolved in water-miscible organic solvent, 
and then nanocapsules can be prepared by slowly dripping 
the mixed solvent into aqueous solution by stirring with or 
without surfactants.26
The release of PEG–PLA block 
copolymer nanoparticles
The release mechanism of PeG–PLA 
block copolymer nanoparticles
The release mechanism of PEG–PLA nanoparticles is 
similar to that of general nanoparticles, and the common 
mechanisms include three types: 1) adsorption and desorp-
tion of drugs on nanoparticles surface; 2) diffusion release; 
and 3)   degradation of nanomatrix or degradation/diffusion 
collaborative   process.27 The drug release mainly depends on 
the following: 1) desorption of drugs absorbed on the surface 
or interface; 2) diffusion by nanoparticle matrix; 3) diffusion 
through the copolymer wall (nanocapsules); 4) dissolution 
of nanomatrix; and 5) dissolution or diffusion of bond com-
pounds. Therefore, the process of drug release is controlled 
by drug diffusion and matrix degradation.28
The release mechanism for most nanoparticles can be 
divided into two phases: the burst release phase and con-
trolled release phase. In the burst release phase, drugs diffuse 
quickly in the solvent medium due to drugs adsorbing or weak 
bonding onto the surface of nanoparticles with a large surface 
area. Because drugs are not uniformly distributed/dissolved 
in the matrix (hydrophobic chain), in the controlled release 
phase the drug release by diffusion or erosion (degradation) 
depends on the characteristics of the drug delivery system. 
The drug release mainly depends on diffusion when the rate 
of drug diffusion is greater than that of matrix degradation; 
otherwise, it mainly depends on matrix degradation when 
the rate of drug diffusion is less.29 Li et al21 used the volatile 
dialysis method with organic solvent to prepare all-trans 
retinoic acid-loaded nanomicelles and then analyzed the 
release mechanism of nanomicelles. It was found that in 
ensuring the integrity of nanoparticles, by using the mixture 
of phosphate-buffered saline (PBS) (pH 7.4) and ethanol 
(with the proportion of 9:1) as the release medium, the burst 
release occurred in the first 15 h, and then the controlled 
release occurred. Because nanoparticles were complete 
and not degraded in the above condition, the drug release 
mechanism was considered as diffusion after dissolution. 
Over 80% of drugs had been released after 5 days. Mean-
while, in another method, the drug-loaded nanomicelles 
were incubated in PBS, and then the molecular weight was 
analyzed by nuclear magnetic resonance. It was found that 
the nanomicelles were slowly degraded. The degradation 
time of 27.6% of mPEG5–PLA5 and 30.1% of mPEG2–PLA16 
was more than 30 days. Therefore, the release mechanism 
of all-trans retinoic acid-loaded mPEG–PLA nanomicelles 
was considered as mainly relying on drug diffusion rather 
than matrix degradation.
However, drug release can be induced by physical or 
chemical methods. Light,30 temperature,31 pH,32 power,33 
magnetic field,34 and ultrasound19 have been used to control 
drug release from copolymer nanoparticles.
Influencing factors on drug release 
of PeG–PLA block copolymer 
nanoparticles
PEG–PLA block copolymer is an amphiphilic polymer with 
good stability in vivo. With good biocompatibility, the PEG 
hydrophilic layer can increase the solubility of insoluble 
drugs, effectively prevent the protein absorbed on the nano-
particle surface, make nanoparticles unrecognizable by the 
reticuloendothelial system as foreign bodies, and thereby 
show a characteristic of long circulation. Many factors may 
influence drug release of PEG–PLA block copolymer nano-
particles. The main factors are as follows:
1.	 Molecular weight, chain length of PEG or PLA, and 
PEG/PLA ratio in the polymer: The chain length of PEG 
and PLA can be controlled by changing the molecular International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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weight of PEG and the concentrations of PEG and PLA. 
The longer the PLA chain length, the larger would be the 
nanoparticle size and the drug loading of hydrophobic 
drugs. As the PEG content and weight-average molecular 
weight (Mw) of PLA–PEG–PLA copolymers increased, 
the amount of drug release increased and the total Mw 
of copolymers of nanoparticles decreased. Drug release 
from nanoparticles could potentially be controlled by 
changing the content of PEG, Mw of PEG, and total Mw 
of copolymer.35 It was found by Yang et al36 that the longer 
the PLA chain length, the larger the diameter of micelles 
and drug-loaded micelles would be. An in vitro release 
test showed that the longer the PLA chain length, the 
greater the interaction between PLA chain and hydropho-
bic drug would be and the slower the drug release rate of 
micelles would be. In case of a low Mw of PEG, deforma-
tion occurs easily due to the small molecular chain and 
low flexibility. The greater the molecular weight of PEG, 
the longer the PEG molecular chain length will be and 
the more stable the structure will be. The increase of PLA 
block Mw in the copolymer will reduce significantly the 
stability of nanoparticles and even lead to condensation 
in the solvent.21
2.	 Preparation methods and conditions of PEG–PLA block 
copolymer nanoparticles: Different preparation technolo-
gies of nanoparticles will influence the crystal shape of 
polymer, drug distribution, and stability in the carrier 
materials; influence the surface morphology, particle 
size, and internal compactness of nanoparticles; and thus 
influence the rate and degree of drug release.37
3.	 Particle size of PEG–PLA block copolymer nanopar-
ticles: The particle size of PEG–PLA block copolymer 
nanoparticles can be changed by adjusting PEG chain 
length and PEG/PLA ratio or using a different prepara-
tion method. PEG–PLA block copolymer nanoparticles 
with different sizes will lead to different degradation or 
diffusion rates of nanomatrix, resulting in differences in 
drug release.38
4.	 Drug loading of PEG–PLA block copolymer nanopar-
ticles: Drug loading of PEG–PLA block copolymer 
nanoparticles is also an important influencing factor 
for drug release. The relationship between drug loading 
and micelle stability was studied by Huh et al,39 and it 
was found that due to the incorporation of hydrophobic 
drugs, the micellar hydrophilic–hydrophobic balance was 
destroyed, and the stability of micelles would be increased 
with drug loading decreased. When the paclitaxel loading 
of PEG–PLA micelles was 17.6%, the paclitaxel would 
be dissolved completely in sodium salicylate solution 
after 5 days, whereas in the case of loading capacity of 
27.6%, the paclitaxel would be dissolved completely 
after 3 days.
In addition to the above major influencing factors, drug 
release will be influenced by copolymer concentration,40 pH,41 
zeta potential,42 and solvents.43
Surface modification of PEG–PLA 
block copolymer nanoparticles
By modifying the surface of PEG–PLA block copolymer 
nanoparticles, various special nanoparticles may be prepared 
in order to increase the therapeutic effect of drugs, such as 
long-circulating nanoparticles, immunonanoparticles, ther-
mosensitive nanoparticles, and pH-sensitive nanoparticles. 
Common materials for surface modification include three 
types: 1) polysaccharides such as cyclodextrin and chitosan; 
2) surfactants such as polysorbate; and 3) PEG poloxamer. 
Due to their core shell structure, the surface of PEG–PLA 
block copolymer nanoparticles is often modified by folic 
acid, peptide, lectin, and albumin. Compared with PEG–PLA 
block copolymer nanoparticles with passive targeting, these 
modified nanoparticles can actively target special locations 
for enhancing drug efficacy and decreasing drug toxicity. 
For example, PEG–PLA nanoparticles with surface-bound 
lectins (biorecognitive ligands) were established by Gao 
et al.44 Due to abundant N-acetyl-d-glucosamine and sialic 
acid in the nasal cavity, wheat germ agglutinin was selected 
as a model lectin to bind them. The resulting nanoparticles 
increased significantly the uptake of drugs in the brain asso-
ciated with nanoparticles through intranasal delivery, which 
might provide a novel effective noninvasive technique for 
drug delivery to the brain, particularly for biotech drugs 
such as peptides, proteins, and DNA. Yu et al45 synthesized 
the aldehyde–PEG–PLA block copolymer by ring-opening 
polymerization and conjugated a peptide (K237 ligand) to the 
aldehyde group of PEG chain by using the N-terminal PEGy-
lation technique. The K237-conjugated paclitaxel nanopar-
ticles could be significantly internalized by human umbilical 
vein endothelial cells through the K237-KDR (K237-vascular 
endothelial growth factor receptor) interaction. This facili-
tated uptake of paclitaxel led to the enhanced antiangiogenic 
activity, migration, and tube formation compared with cells 
treated with paclitaxel nanoparticles and commercial taxol. 
PEG–PLA block copolymer nanoparticles modified with 
folic acid or its salts as target materials can accumulate International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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in cancer locations, increase drug concentration in cancer 
locations, and prolong the action time. Tsai et al46 prepared 
poly(HEMA-co-histidine)-g-PLA and folate-PEG–PLA 
nanomicelles. Folate for cancer-specific target was bound at 
the end of the polymer chain. It was found that cellular uptake 
of folate micelles was higher than that of non-folate micelles 
due to the folate-binding effect on the cell membrane. An in 
vivo study of folate micelles exhibited cancer targeting and 
effective inhibition of tumor growth.
Application of PEG–PLA block 
copolymer nanoparticles in 
pharmaceutical preparation
The PEG–PLA copolymer has the advantages of both PEG 
and PLA. As a drug carrier, PEG–PLA copolymer nanopar-
ticles have some advantages, eg, 1) reducing the first-pass 
effect and increasing bioavailability;47 2) increasing drug 
loading and encapsulation efficiency;48 3) reducing particle 
size and burst release while improving targeting;49 4)   avoiding 
recognition and removal by the reticuloendothelial system, 
thereby prolonging the circulation time of drugs in the blood 
and improving stability;50 and 5) good safety.9 In many 
  studies, PEG–PLA block copolymer nanoparticles were used 
as carriers for vaccine, protein, and gene drugs, particularly 
in a sustained/controlled release drug delivery system and 
targeted-drug delivery system that could enhance drug effi-
cacy and reduce drug resistance.51
Sustained and controlled  
release drug delivery system
PEG–PLA copolymer nanoparticles are mainly diffusion 
and degradation controlled release systems. Hydrophobic 
drugs mainly accumulate in the hydrophobic matrix. In dif-
fusion controlled systems, drugs are dissolved or dispersed 
in PLA polymers, and the release rate is controlled by drug 
diffusion through a PLA matrix. The drugs adjacent to the 
membrane surface can be released smoothly, whereas drugs 
inside the membrane are required to be diffused to the mem-
brane surface first and then are released successfully. In the 
degradation controlled system, drugs are dispersed in PLA, 
and the drug release rate is determined by degradation rate 
due to influences from PLA chain length, drug loading of 
nanoparticles, release medium, and other factors.
PEG–PLA and PLA nanoparticle mixture loaded 
with betamethasone disodium phosphate was prepared by 
Ishihara et al.52 Taking inflammation mice as a model, the 
anti-inflammatory activity was found to be partly weakened 
by nanoparticles. With in vitro detection on nanoparticle 
degradation, PEG chains on the surface of nanoparticles 
disappeared in a few days and then the drug was slowly 
released. These nanoparticles accumulated at inflammation 
and injury locations preferentially, and a large amount of 
drugs was gradually degraded from these locations with the 
duration of more than 14 days.
PEG–PLA nanoparticles do not change the spatial config-
uration of proteins, antigens, and other bioactive substances 
to maintain their biological activities. Meanwhile, PEG–PLA 
copolymer nanoparticles loaded with proteins may avoid the 
degradation of proteins by proteases in the blood, reduce the 
recognition of immune cells, and enhance stability, so that 
protein inactivation is not able to occur easily. Thus, they are 
particularly suitable as a biotech drug carrier, especially for 
oral controlled release delivery of proteins and enzymes.53,54 
The protein drug and gene therapeutic agents encapsulated 
in PEG–PLA block copolymer nanoparticles for sustained/
controlled release may improve therapeutic effects of drugs 
and the quality of life of patients, and consequently the 
nanoparticles have become popular carriers for proteins and 
gene drugs. For example, Rafat et al15 evaluated PEG–PLA 
microparticles for encapsulation and delivery of a transac-
tivator of transcription-enhanced green fluorescent protein 
fusion (Tat-EGFP) to retinal cells. The results suggested 
that PEG–PLA microparticles can deliver proteins in cell 
culture, allowing protein internalization in as little as 1 h. In 
vivo, protein was shown to localize within the photoreceptor 
layer of the retina and persist for at least 9 weeks with no 
observed toxicity.
Targeted drug delivery system
PEG–PLA nanoparticles with a narrow distribution of par-
ticle size have a smaller particle size than PLA nanoparticles. 
Thus, they may accumulate easily in inflammation locations 
and then slowly release the drugs. In particular, targeting 
molecules can be introduced in the PEG terminal to enhance 
active targeting. Therefore, the combination of passive and 
active targeting can act effectively on lesion locations. The 
carboxy-PEG–PLA block copolymer was synthesized by 
Ueki et al55 and was used to prepare camptothecin nanopar-
ticles. The results showed that nanoparticles can effectively 
improve the delivery efficiency of camptothecin to the tumor 
location. Wang et al56 successfully prepared combretastatin 
A4(CA4)-loaded nanomicelles. Arg–Gly–Asp (RGD) pep-
tides were coupled to the surface of nanomicelles. It was 
concluded that RGD-targeted micelles significantly enhanced International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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the cell uptake of encapsulated drug in angiogenic tumor 
endothelial cells, which also resulted in increased antiprolif-
erative activity of antivascular agent. Additionally, a lectin-
PEG–PLA nanoparticle drug delivery system was established 
by Gao et al.44 The retention of the biorecognitive activity of 
lectin after the covalent coupling procedure was confirmed 
by hemagglutination test. Taking coumarin as a fluorescent 
marker, the results showed that the nanoparticles modified 
by lectin could be quickly delivered into the brain by nasal 
administration, and the brain’s uptake of coumarin carried 
by lectin-functionalized nanoparticles was about two-fold 
in different brain tissues compared with that of coumarin 
incorporated in the unmodified ones. In the meantime, it has 
a higher application security. Due to the hydrophilic chain 
of PEG, it can stay longer in the nasal cavity and facilitate 
nanoparticles through cell transit. Moreover, after linking 
modifiers of special biological activity in the PEG–PLA 
chain end, such as peptide, amino acid, and protein,57–59 drugs 
in PEG–PLA nanoparticles can enter the brain through the 
blood–brain barrier.
Conclusions and prospects
In conclusion, with their biodegradability, good biocompat-
ibility, and amphiphilic characteristics, PEG–PLA block 
copolymers can be prepared into various nanoparticles. 
By adjusting the content and Mw of PLA and PEG and 
the PEG/PLA ratio, the block copolymers can increase the 
drug loading and encapsulation efficiency of hydrophobic 
drugs, reduce particle sizes, avoid recognition by the reticu-
loendothelial system, and prolong blood circulation time. 
However, the long circulating property of PEG–PLA block 
copolymer nanoparticles is required to be improved further. 
Additionally, due to small particle sizes and large surface 
areas of nanoparticles with surface adsorption, the first-pass 
effect still exists, and blood clearance can also be accelerated. 
Otherwise, the synthesis of PEG–PLA block copolymer by 
the lactide ring-opening polymerization method is expen-
sive and not suitable for large-scale production, whereas 
the polymer prepared by a direct method has a lower Mw 
with a wider distribution. The current studies on PEG–PLA 
nanoparticles are still performed in the laboratory, and there 
is a long way to go on how to make technologies more stable 
and mature and ultimately promote large-scale production 
for clinical application. PEG–PLA nanoparticles can be 
expected to provide more tools and possibilities for the clini-
cal treatment of diseases with broad application prospects in 
  pharmaceutical preparations.
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